Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Email your doctor to beat gout: new trial tests remote care

NCT ID NCT04733079

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether regular email communication between gout patients and their doctors can help lower uric acid levels more effectively than standard care. 204 adults with confirmed gout will either follow usual care or use a secure messaging system to adjust their medication dose until their uric acid target is reached. The goal is to see if this remote, treat-to-target approach can improve gout control and reduce flares.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cleanweb electronic messaging ePro
What this could lead to
If successful, this could offer a simple, remote way to manage gout effectively, reducing flares and complications.
What could go wrong
This is a relatively small, early-stage trial comparing email follow-up to usual care. The approach may not work for everyone, and results may not apply to all gout patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 204 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged over 18 years old * Gout confirmed by identification of urate crystals by joint fluid or tophus analysis or by ultrasound of the affected joint or * Gout according to Nijmegen criteria (presence of a score ≥ 8/13) depending on the following items: Man (2 pts) Previous crisis (2 pts) Involvement of first metatarsophalangeal joint (MTP1) (2.5 pts) Maximum pain within 24 hours (0.5pt) Redness (1 pt) HTA or cardiovascular disease (1.5 pts) SUL \> 360 μmol/l during the crisis (3.5 pts) * Patients without ULT or with an ineffective ULT defined by an SUL \> 360 μmol/l in intercritical pahse * Patients who routinely use e-mail Exclusion Criteria: * Participating in another trial including the administration of a drug * Patients treated with azathioprine * Patients intolerant to hypouricemic treatments * Unable to use the internet * Difficulty understanding French * Illiteracy * Pregnant womenor breastfeeding mothers (see PHC article L.1121-5) * Persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care under Sections L. 3212-1 and L. 3213-1 and persons admitted to a health or social institution for purposes other than research (see CSP Article L.1121-6) * Major persons subject to a measure of legal protection or unseeding to express consent (see PHC Article L.1121-8) * Persons not affiliated to a social security plan or beneficiaries of such a plan (see PHC Article L.1121-8-1)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gout are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gout Hyperuricemia Patient Compliance rheumatic disorder rheumatic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gout Hyperuricemia Inflammatory rheumatism Posology adjustment

Contacts and locations

Locations

  • Hopital LARIBOISIERE - Rhumatologie

    Paris, 75010, France

  • Rhumathology department

    Paris, Île-de-France Region, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.